Certain L-Tryptophan, L-Tryptophan Products, and Their Methods of Production; Commission Final Determination Finding a Section 337 Violation; Issuance of a Limited Exclusion Order and Cease and Desist Order; Termination of the Investigation, 60763-60764 [2017-27567]
Download as PDF
Federal Register / Vol. 82, No. 245 / Friday, December 22, 2017 / Notices
amended (19 U.S.C. 1337), and in
section 210.75 of the Commission’s
Rules of Practice and Procedure (19 CFR
210.75).
By order of the Commission.
Issued: December 18, 2017.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2017–27568 Filed 12–21–17; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1005]
Certain L-Tryptophan, L-Tryptophan
Products, and Their Methods of
Production; Commission Final
Determination Finding a Section 337
Violation; Issuance of a Limited
Exclusion Order and Cease and Desist
Order; Termination of the Investigation
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission has found a violation of
section 337 of the Tariff Act of 1930
(‘‘section 337’’), as amended, in this
investigation. The Commission has
issued a limited exclusion order
prohibiting the importation of certain Ltryptophan and L-tryptophan products
that infringe claim 10 of U.S. Patent No.
6,180,373 (‘‘the ’373 patent’’) or claim
20 of U.S. Patent No. 7,666,655 (‘‘the
’655 patent’’). The Commission has also
issued a cease and desist order directed
to the domestic respondent. The
investigation is terminated.
FOR FURTHER INFORMATION CONTACT:
Houda Morad, Office of the General
Counsel, U.S. International Trade
Commission, 500 E Street SW,
Washington, DC 20436, telephone (202)
708–4716. Copies of non-confidential
documents filed in connection with this
investigation are or will be available for
inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the
Office of the Secretary, U.S.
International Trade Commission, 500 E
Street SW, Washington, DC 20436,
telephone (202) 205–2000. General
information concerning the Commission
may also be obtained by accessing its
internet server at https://www.usitc.gov.
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:59 Dec 21, 2017
Jkt 244001
contacting the Commission’s TDD
terminal on (202) 205–1810.
The
Commission instituted Investigation No.
337–TA–1005 on June 14, 2016, based
on a complaint filed by Complainants
Ajinomoto Co., Inc. of Tokyo, Japan and
Ajinomoto Heartland Inc. of Chicago,
Illinois (collectively, ‘‘Ajinomoto’’ or
‘‘Complainants’’). See 81 FR 38735–6
(June 14, 2016). The complaint, as
supplemented, alleges violations of
section 337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), based upon
the importation into the United States,
the sale for importation, and the sale
within the United States after
importation of certain L-tryptophan, Ltryptophan products, and their methods
of production, by reason of infringement
of certain claims of the ’655 patent and
the ’373 patent (collectively, ‘‘the
asserted patents’’). Id. The notice of
investigation identified CJ CheilJedang
Corp. of Seoul, Republic of Korea; CJ
America, Inc. (‘‘CJ America’’) of
Downers Grove, Illinois; and PT
CheilJedang Indonesia of Jakarta,
Indonesia (collectively ‘‘CJ’’ or
‘‘Respondents’’) as respondents in this
investigation. See id. The Office of
Unfair Import Investigations is not a
party to the investigation.
On April 17, 2017, the ALJ issued an
initial determination (‘‘ID’’) granting
Complainants’ unopposed motion for
summary determination that they satisfy
the economic prong of the domestic
industry requirement under 19 U.S.C.
1337(a)(3)(A) and (B) for both asserted
patents. See Order No. 18, unreviewed,
Comm’n Notice (May 17, 2017).
On August 11, 2017, the ALJ issued
his final initial determination (‘‘FID’’)
finding no violation of section 337.
Specifically, the FID finds that: (1)
Respondents’ accused products do not
infringe the asserted claims of the ’373
or the ’655 patents either literally or
under the doctrine of equivalents; (2)
claim 10 of the ’373 patent is invalid for
indefiniteness and lack of written
description; (3) claim 20 of the ’655
patent is invalid for lack of written
description; and (4) Complainants’
products do not satisfy the technical
prong of the domestic industry
requirement with respect to the ’655 or
the ’373 patents. In addition, the ALJ
issued a Recommended Determination
(‘‘RD’’) recommending, should the
Commission find a section 337
violation, that the Commission issue: (1)
A limited exclusion order against
Respondents’ accused products; and (2)
a cease and desist order against
Respondent CJ America. The RD further
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
60763
recommends no bond during the
Presidential review period.
On August 14, 2017, the Commission
issued a Notice requesting written
submissions on the public interest. See
82 FR 39456–57 (Aug. 18, 2017). On
September 20, 2017, Respondents filed
a written submission in response to the
Commission’s August 14, 2017 Notice.
No other submissions were received.
On October 12, 2017, the Commission
issued a Notice determining to review
the FID in its entirety. See 82 FR 48528–
29 (Oct. 18, 2017). The October 12, 2017
Notice requested briefing in response to
certain questions relating to the FID’s
finding of no section 337 violation. See
id. In addition, the October 12, 2017
Notice solicited written submissions on
issues of remedy, the public interest,
and bonding. See id. On October 27,
2017, the parties filed written
submissions in response to the October
12, 2017 Notice, and on November 3,
2017, the parties filed responses to each
other’s submissions.
Having examined the record of this
investigation, including the FID, the RD,
and the parties’ submissions, the
Commission has determined to:
(1) Reverse the FID’s finding that the
accused products do not infringe claim
10 of the ’373 patent;
(2) reverse the FID’s finding that the
domestic industry requirement is not
satisfied for the ’373 patent.
(3) Reverse the FID’s finding that
claim 10 of the ’373 patent is invalid
under 35 U.S.C. 112, second paragraph,
for indefiniteness;
(4) reverse the FID’s finding that claim
10 of the ’373 patent is invalid under 35
U.S.C. 112, first paragraph, for lack of
written description;
(5) affirm the FID’s finding that claim
10 of the ’373 patent is not invalid
under 35 U.S.C. 112, first paragraph, for
lack of enablement;
(6) affirm the FID’s finding that claim
10 of the ’373 patent is not invalid
under 35 U.S.C. 103 for obviousness;
(7) affirm in part and reverse in part
the FID’s finding that the accused
products do not infringe claim 20 of the
’655 patent;
(8) reverse the FID’s finding that the
domestic industry requirement is not
satisfied for the ’655 patent.
(9) Affirm the FID’s finding that claim
20 of the ’655 patent is not invalid
under 35 U.S.C. 112, second paragraph,
for indefiniteness.
(10) Reverse the FID’s finding that
claim 20 of the ’655 patent is invalid
under 35 U.S.C. 112, first paragraph, for
lack of written description; and
(11) affirm all other findings in the
FID that are not inconsistent with the
Commission’s determination.
E:\FR\FM\22DEN1.SGM
22DEN1
60764
Federal Register / Vol. 82, No. 245 / Friday, December 22, 2017 / Notices
Accordingly, the Commission finds
that there is a violation of section 337
with respect to both asserted patents.
The Commission has determined the
appropriate remedy is a limited
exclusion order against Respondents’
accused products, and a cease and
desist order against Respondent CJ
America. The Commission has also
determined that the public interest
factors enumerated in subsections
337(d)(l) and (f)(1) (19 U.S.C. 1337(d)(l),
(f)(1)) do not preclude issuance of the
limited exclusion order and cease and
desist order. The Commission has
further determined to set a bond at zero
(0) percent of entered value during the
Presidential review period (19 U.S.C.
1337(j)).
The Commission’s orders and opinion
were delivered to the President and to
the United States Trade Representative
on the day of their issuance.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
By order of the Commission.
Issued: December 18, 2017.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2017–27567 Filed 12–21–17; 8:45 am]
BILLING CODE 7020–02–P
JUDICIAL CONFERENCE OF THE
UNITED STATES
Hearings of the Judicial Conference
Advisory Committee on the Federal
Rules of Bankruptcy Procedure
Advisory Committee on the
Federal Rules of Bankruptcy Procedure,
Judicial Conference of the United States.
AGENCY:
Notice of cancellation of public
hearing.
ACTION:
The following public hearing
on proposed amendments to the Federal
Rules of Bankruptcy Procedure has been
canceled: Bankruptcy Rules Hearing on
January 17, 2018, in Washington, DC.
SUMMARY:
sradovich on DSK3GMQ082PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Rebecca A. Womeldorf, Rules
Committee Secretary, Rules Committee
Staff, Administrative Office of the
United States Courts, Washington, DC
20544, telephone (202) 502–1820.
SUPPLEMENTARY INFORMATION:
Announcement for this hearing was
previously published in 82 FR 37610.
VerDate Sep<11>2014
16:59 Dec 21, 2017
Jkt 244001
Dated: December 19, 2017.
Rebecca A. Womeldorf,
Rules Committee Secretary.
[FR Doc. 2017–27614 Filed 12–21–17; 8:45 am]
BILLING CODE 2210–55–P
DEPARTMENT OF JUSTICE
[OMB Number 1122–0011]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Extension of a
Currently Approved Collection
Office on Violence Against
Women, Department of Justice.
ACTION: 30-Day notice.
AGENCY:
The Department of Justice,
Office on Violence Against Women
(OVW) will be submitting the following
information collection request to the
Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The proposed
information collection was previously
published in the Federal Register on
September 9, 2017, allowing for a 60
day comment period.
DATES: Comments are encouraged and
will be accepted for 30 days until
January 22, 2018.
FOR FURTHER INFORMATION CONTACT:
Written comments and/or suggestion
regarding the items contained in this
notice, especially the estimated public
burden and associated response time,
should be directed to Cathy Poston,
Office on Violence Against Women, at
202–514–5430 or Catherine.poston@
usdoj.gov. Written comments and/or
suggestions can also be sent to the
Office of Management and Budget,
Office of Information and Regulatory
Affairs, Attention Department of Justice
Desk Officer, Washington, DC 20530 or
sent to OIRA_submissions@
omb.eop.gov.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(2) Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
SUMMARY:
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and
(4) Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
Overview of This Information
Collection
(1) Type of Information Collection:
Extension of a currently approved
collection.
(2) Title of the Form/Collection: SemiAnnual Progress Report for Grantees
from the Grants to Support Tribal
Domestic Violence and Sexual Assault
Coalitions Program (Tribal Coalitions
Program).
(3) Agency form number, if any, and
the applicable component of the
Department of Justice sponsoring the
collection: Form Number: 1122–0011.
U.S. Department of Justice, Office on
Violence Against Women.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: The affected public includes
the 14 grantees from the Tribal
Coalitions Program. The Tribal
Coalitions Program grantees include
Indian tribal governments that will
support the development and operation
of new or existing nonprofit tribal
domestic violence and sexual assault
coalitions in Indian country. These
grants provide funds to develop and
operate nonprofit tribal domestic
violence and sexual assault coalitions in
Indian country to address the unique
issues that confront Indian victims. The
Tribal Coalitions Program provides
resources for organizing and supporting
efforts to end violence against Indian
women.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond/reply: It is estimated that it will
take the 14 respondents (grantees from
the Tribal Coalitions Program)
approximately one hour to complete a
Semi-Annual Progress Report. The
Semi-Annual Progress Report is divided
into sections that pertain to the different
types of activities that grantees may
engage in with grant funds. Grantees
must complete only those sections that
are relevant to their activities.
(6) An estimate of the total public
burden (in hours) associated with the
collection: The total annual hour burden
to complete the data collection forms is
28 hours, that is 14 grantees completing
E:\FR\FM\22DEN1.SGM
22DEN1
Agencies
[Federal Register Volume 82, Number 245 (Friday, December 22, 2017)]
[Notices]
[Pages 60763-60764]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-27567]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation No. 337-TA-1005]
Certain L-Tryptophan, L-Tryptophan Products, and Their Methods of
Production; Commission Final Determination Finding a Section 337
Violation; Issuance of a Limited Exclusion Order and Cease and Desist
Order; Termination of the Investigation
AGENCY: U.S. International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the U.S. International Trade
Commission has found a violation of section 337 of the Tariff Act of
1930 (``section 337''), as amended, in this investigation. The
Commission has issued a limited exclusion order prohibiting the
importation of certain L-tryptophan and L-tryptophan products that
infringe claim 10 of U.S. Patent No. 6,180,373 (``the '373 patent'') or
claim 20 of U.S. Patent No. 7,666,655 (``the '655 patent''). The
Commission has also issued a cease and desist order directed to the
domestic respondent. The investigation is terminated.
FOR FURTHER INFORMATION CONTACT: Houda Morad, Office of the General
Counsel, U.S. International Trade Commission, 500 E Street SW,
Washington, DC 20436, telephone (202) 708-4716. Copies of non-
confidential documents filed in connection with this investigation are
or will be available for inspection during official business hours
(8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S.
International Trade Commission, 500 E Street SW, Washington, DC 20436,
telephone (202) 205-2000. General information concerning the Commission
may also be obtained by accessing its internet server at https://www.usitc.gov. The public record for this investigation may be viewed
on the Commission's electronic docket (EDIS) at https://edis.usitc.gov.
Hearing-impaired persons are advised that information on this matter
can be obtained by contacting the Commission's TDD terminal on (202)
205-1810.
SUPPLEMENTARY INFORMATION: The Commission instituted Investigation No.
337-TA-1005 on June 14, 2016, based on a complaint filed by
Complainants Ajinomoto Co., Inc. of Tokyo, Japan and Ajinomoto
Heartland Inc. of Chicago, Illinois (collectively, ``Ajinomoto'' or
``Complainants''). See 81 FR 38735-6 (June 14, 2016). The complaint, as
supplemented, alleges violations of section 337 of the Tariff Act of
1930, as amended (19 U.S.C. 1337), based upon the importation into the
United States, the sale for importation, and the sale within the United
States after importation of certain L-tryptophan, L-tryptophan
products, and their methods of production, by reason of infringement of
certain claims of the '655 patent and the '373 patent (collectively,
``the asserted patents''). Id. The notice of investigation identified
CJ CheilJedang Corp. of Seoul, Republic of Korea; CJ America, Inc.
(``CJ America'') of Downers Grove, Illinois; and PT CheilJedang
Indonesia of Jakarta, Indonesia (collectively ``CJ'' or
``Respondents'') as respondents in this investigation. See id. The
Office of Unfair Import Investigations is not a party to the
investigation.
On April 17, 2017, the ALJ issued an initial determination (``ID'')
granting Complainants' unopposed motion for summary determination that
they satisfy the economic prong of the domestic industry requirement
under 19 U.S.C. 1337(a)(3)(A) and (B) for both asserted patents. See
Order No. 18, unreviewed, Comm'n Notice (May 17, 2017).
On August 11, 2017, the ALJ issued his final initial determination
(``FID'') finding no violation of section 337. Specifically, the FID
finds that: (1) Respondents' accused products do not infringe the
asserted claims of the '373 or the '655 patents either literally or
under the doctrine of equivalents; (2) claim 10 of the '373 patent is
invalid for indefiniteness and lack of written description; (3) claim
20 of the '655 patent is invalid for lack of written description; and
(4) Complainants' products do not satisfy the technical prong of the
domestic industry requirement with respect to the '655 or the '373
patents. In addition, the ALJ issued a Recommended Determination
(``RD'') recommending, should the Commission find a section 337
violation, that the Commission issue: (1) A limited exclusion order
against Respondents' accused products; and (2) a cease and desist order
against Respondent CJ America. The RD further recommends no bond during
the Presidential review period.
On August 14, 2017, the Commission issued a Notice requesting
written submissions on the public interest. See 82 FR 39456-57 (Aug.
18, 2017). On September 20, 2017, Respondents filed a written
submission in response to the Commission's August 14, 2017 Notice. No
other submissions were received.
On October 12, 2017, the Commission issued a Notice determining to
review the FID in its entirety. See 82 FR 48528-29 (Oct. 18, 2017). The
October 12, 2017 Notice requested briefing in response to certain
questions relating to the FID's finding of no section 337 violation.
See id. In addition, the October 12, 2017 Notice solicited written
submissions on issues of remedy, the public interest, and bonding. See
id. On October 27, 2017, the parties filed written submissions in
response to the October 12, 2017 Notice, and on November 3, 2017, the
parties filed responses to each other's submissions.
Having examined the record of this investigation, including the
FID, the RD, and the parties' submissions, the Commission has
determined to:
(1) Reverse the FID's finding that the accused products do not
infringe claim 10 of the '373 patent;
(2) reverse the FID's finding that the domestic industry
requirement is not satisfied for the '373 patent.
(3) Reverse the FID's finding that claim 10 of the '373 patent is
invalid under 35 U.S.C. 112, second paragraph, for indefiniteness;
(4) reverse the FID's finding that claim 10 of the '373 patent is
invalid under 35 U.S.C. 112, first paragraph, for lack of written
description;
(5) affirm the FID's finding that claim 10 of the '373 patent is
not invalid under 35 U.S.C. 112, first paragraph, for lack of
enablement;
(6) affirm the FID's finding that claim 10 of the '373 patent is
not invalid under 35 U.S.C. 103 for obviousness;
(7) affirm in part and reverse in part the FID's finding that the
accused products do not infringe claim 20 of the '655 patent;
(8) reverse the FID's finding that the domestic industry
requirement is not satisfied for the '655 patent.
(9) Affirm the FID's finding that claim 20 of the '655 patent is
not invalid under 35 U.S.C. 112, second paragraph, for indefiniteness.
(10) Reverse the FID's finding that claim 20 of the '655 patent is
invalid under 35 U.S.C. 112, first paragraph, for lack of written
description; and
(11) affirm all other findings in the FID that are not inconsistent
with the Commission's determination.
[[Page 60764]]
Accordingly, the Commission finds that there is a violation of
section 337 with respect to both asserted patents. The Commission has
determined the appropriate remedy is a limited exclusion order against
Respondents' accused products, and a cease and desist order against
Respondent CJ America. The Commission has also determined that the
public interest factors enumerated in subsections 337(d)(l) and (f)(1)
(19 U.S.C. 1337(d)(l), (f)(1)) do not preclude issuance of the limited
exclusion order and cease and desist order. The Commission has further
determined to set a bond at zero (0) percent of entered value during
the Presidential review period (19 U.S.C. 1337(j)).
The Commission's orders and opinion were delivered to the President
and to the United States Trade Representative on the day of their
issuance.
The authority for the Commission's determination is contained in
section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and
in part 210 of the Commission's Rules of Practice and Procedure (19 CFR
part 210).
By order of the Commission.
Issued: December 18, 2017.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2017-27567 Filed 12-21-17; 8:45 am]
BILLING CODE 7020-02-P